Enrique García-Boll

Enrique García-Boll

Auto-generated profile, based on publicly available information

Enrique García-Boll

Instituto de Neurobiología, Universidad Nacional Autónoma de México, Blvd. Juriquilla 3001, 76230 Querétaro. Mexico

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Neuropharmacology
Verified
Journal Article
Closed access
EGEnrique García-Boll
Enrique García-Boll
GMGuadalupe Martínez-Lorenzana
Guadalupe Martínez-Lorenzana
MCMiguel Condés-Lara
Miguel Condés-Lara
Abimael González-HernándezAbimael González-Hernández
Abimael González-Hernández

1 January 2020 in Experimental Neurology
Verified
Journal Article
Closed access
EGEnrique García-Boll
Enrique García-Boll
GMGuadalupe Martínez-Lorenzana
Guadalupe Martínez-Lorenzana
MCMiguel Condés-Lara
Miguel Condés-Lara
Abimael González-HernándezAbimael González-Hernández
Abimael González-Hernández

13 November 2020 in CNS & Neurological Disorders - Drug Targets
Verified
Journal Article
Closed access
PDF file
Abimael González-HernándezAbimael González-Hernández
Abimael González-Hernández
BMBruno Antonio Marichal-Cancino
Bruno Antonio Marichal-Cancino
EGEnrique García-Boll
Enrique García-Boll
CVCarlos M. Villalón
Carlos M. Villalón
Migraine is a complex neurovascular disorder characterized by attacks of moderate to severe unilateral headache, accompanied by photophobia among other neurological signs. Although an arsenal of antimigraine agents is currently available in the market, not all patients respond to them. As Calcitonin Gene-Related Peptide (CGRP) plays a key role in the pathophysiology of migraine, CGRP receptor antagonists (gepants) have been developed. Unfortunately, further pharmaceutical development (for olcegepant and telcagepant) was interrupted due to pharmacokinetic issues observed during the Randomized Clinical Trials (RCT). On this basis, the use of monoclonal antibodies (mAbs; immunoglobulins) against CGRP or its receptor has recently emerged as a novel pharmacotherapy to treat migraines. RCT showed that these mAbs are effective against migraines producing fewer adverse events. Presently, the U.S. Food and Drug Administration approved four mAbs, namely: (i) erenumab; (ii) fremanezumab; (iii) galcanezumab; and (iv) eptinezumab. In general, specific antimigraine compounds exert their action in the trigeminovascular system, but the locus of action (peripheral vs. central) of the mAbs remains elusive. Since these mAbs have a molecular weight of ∼150 kDa, some studies rule out the relevance of their central actions as they seem unlikely to cross the Blood-Brain Barrier (BBB). Considering the therapeutic relevance of this new class of antimigraine compounds, the present review has attempted to summarize and discuss the current evidence on the probable sites of action of these mAbs.